The Evil Axis of Obesity, Inflammation and Type-2 Diabetes

E-ISSN： 2212-3873|11|1|23-31

ISSN： 1871-5303

Source： Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol.11, Iss.1, 2011-03, pp. : 23-31

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The use of orlistat in the treatment of obesity, dyslipidaemia and Type 2 diabetes

By Nelson Robert H Miles John M

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 14, 2005-11 ,pp. : 2483-2491

Informa Healthcare

Access to resources Recommend Favorite

Alzheimer's Disease And Type 2 Diabetes: Exploring The Association To Obesity And Tyrosine Hydroxylase

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 11, Iss. 4, 2012-06 ,pp. : 482-489

Bentham Science Publishers

Access to resources Recommend Favorite

DGAT: Novel Therapeutic Target for Obesity and Type 2 Diabetes Mellitus

Current Drug Targets - Immune, Endocrine & Metabolic Disorders, Vol. 3, Iss. 4, 2003-12 ,pp. : 263-270

Bentham Science Publishers

Access to resources Recommend Favorite

Role of oxidative stress and inflammation in the origin of Type 2 diabetes – a paradigm shift

By Pillarisetti Sivaram Saxena Uday

Expert Opinion on Therapeutic Targets, Vol. 8, Iss. 5, 2004-10 ,pp. : 401-408

Informa Healthcare

Access to resources Recommend Favorite

Carbamazepine/citalopram/lithium: Avolition and obesity leading to type 2 diabetes mellitus, in a patient with hypogonadism: case report

Reactions Weekly, Vol. 1, Iss. 1249, 2009-01 ,pp. : 12-13

Adis International

Access to resources Recommend Favorite